Advances and Perspectives in methods for identifying high platelet reactivity
Hua Gao,
Nan Yang,
Libo Yang,
Hui Wang,
Guoshan Zhang,
Xueping Ma,
Ning Deng
Affiliations
Hua Gao
Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, China; School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China
Nan Yang
School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China
Libo Yang
Heart Centre and Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan, 750004, China
Hui Wang
Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, China
Guoshan Zhang
Heart Centre and Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan, 750004, China
Xueping Ma
Heart Centre and Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan, 750004, China; Corresponding author. Heart Centre and Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, No. 804 Shengli South Street, Xingqing District, Yinchuan, 750004, 448910792, China.
Ning Deng
Office of Drug Clinical Trial Organization, General Hospital of Ningxia Medical University, Yinchuan, 750004, China; Corresponding author. Office of Drug Clinical Trial Organization, General Hospital of Ningxia Medical University, No. 804 Shengli South Street, Xingqing District, Yinchuan, 750004, China.
Antiplatelet therapy is the foundational treatment for the prevention and treatment of coronary and cerebrovascular ischemic events in patients with coronary heart disease, ischemic stroke, and transient ischemic attack (TIA). However, with more and more studies reporting an increased risk of thrombosis in some patients due to poor response to therapeutic agents, the selection of appropriate P2Y12 inhibitors has become a major challenge that needs to be addressed urgently. Currently, commonly used oral P2Y12 inhibitors include clopidogrel, ticagrelor, and prasugrel. Assessing patients' risk factors before the development of treatment regimens by effectively predicting the risk of high platelet reactivity with specific P2Y12 inhibitors in advance to avert the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) is the key point to the problem. Up to now, methods available for predicting platelet reactivity include genetic testing, platelet function testing, and risk scores. This review provides a summarization of the existent available identification methods and analyzes the advantages and drawbacks of different methods in specific clinical settings, intending to guide the rational clinical application of P2Y12 receptor inhibitors.
